Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molnupiravir - Emory University/Georgia State University/Merck & Co/Ridgeback Biotherapeutics

X
Drug Profile

Molnupiravir - Emory University/Georgia State University/Merck & Co/Ridgeback Biotherapeutics

Alternative Names: EIDD-2801; LAGEVRIO; MK-4482; Molxvir; Movfor

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University; Georgia State University
  • Developer Emory University; Hetero Labs; Merck & Co; Merck Sharp & Dohme; Ridgeback Biotherapeutics
  • Class Antivirals; Esters; Hydroxylamines; Pyrimidinones; Ribonucleosides; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase II Respiratory syncytial virus infections
  • Phase I Influenza virus infections; Renal failure
  • No development reported Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Middle East respiratory syndrome coronavirus; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis

Most Recent Events

  • 28 May 2024 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (PO)
  • 28 May 2024 No recent reports of development identified for preclinical development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in USA (PO)
  • 28 May 2024 No recent reports of development identified for preclinical development in Severe acute respiratory syndrome(Prevention) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top